2-methyl-4-isothiazolin-3-one hydrochloride (MIT) is a broad-spectrum biocide used as a preservative in a wide range of consumer products, including cosmetics, paints, and cutting fluids. It is effective against bacteria, fungi, and algae. MIT is typically synthesized via the reaction of 2-methyl-4-isothiazolin-3-one with hydrochloric acid. MIT has been shown to be effective in preventing microbial growth in a variety of products. However, there have been reports of allergic reactions and skin irritation associated with exposure to MIT. As a result, there is ongoing research into the safety and efficacy of MIT as a preservative.'
| ID Source | ID |
|---|---|
| PubMed CID | 117746 |
| CHEMBL ID | 1438592 |
| MeSH ID | M0311478 |
| Synonym |
|---|
| 2-methyl-4-isothiazolin-3-one hcl |
| 2-methyl-4-isothiazolin-3-one hydrochloride, >=99% |
| NCGC00164391-01 |
| 2-methyl-4-isothiazolin-3-one hydrochloride |
| smr000875225 |
| MLS001332656 |
| MLS001332655 |
| 2-methyl-3-isothiazolone hydrochloride |
| 2-methyl-3-isothiazolone-d3 hydrochloride |
| tox21_301935 |
| dtxcid9020740 |
| cas-26172-54-3 |
| dtxsid1040740 , |
| NCGC00255684-01 |
| -methyl-2h-isothiazol-3-one hydrochloride |
| AKOS006228350 |
| einecs 247-499-3 |
| 3(2h)-isothiazolone, 2-methyl-, hydrochloride |
| unii-3g9pnz5p41 |
| 26172-54-3 |
| 3(2h)-isothiazolone, 2-methyl-, hydrochloride (1:1) |
| 3g9pnz5p41 , |
| 2-methyl-2h-isothiazol-3-one hydrochloride |
| 2-methyl-3(2h)-isothiazolone hydrochloride |
| FT-0612932 |
| SJXPQSRCFCPWQQ-UHFFFAOYSA-N |
| W-107194 |
| mit hydrochloride |
| CHEMBL1438592 |
| mfcd06804636 |
| 2-methyl-4-isothiazoline-3-one hydrochloride |
| 2-methyl-1,2-thiazol-3-one;hydrochloride |
| 2-methyl-4-isothiazolin-3-one hydrochloride; 2-methylisothiazol-3-one hydrochloride |
| discontinued see m314965 |
| 2-methylisothiazol-3(2h)-one hydrochloride |
| CS-W010959 |
| methylisothiazolinone (hydrochloride) |
| 26172-54-3 (hcl) |
| methylisothiazolinone hcl |
| AMY38474 |
| MS-20344 |
| 2-methylisothiazol-3-one hydrochloride |
| 2-methylisothiazol-3-one (hydrochloride) |
| Q27257186 |
| D92969 |
| HY-W010243 |
| kb-838 |
| 2-methylisothiazol-3(2h)-onehydrochloride |
| 4-(1h-pyrazol-1-ylmethyl)benzoicacid |
| 2-methyl-4-isothiazoline-3-one hcl |
| SY308105 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 5.6234 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 35.0231 | 0.0072 | 15.7588 | 89.3584 | AID1224835; AID588342 |
| acetylcholinesterase | Homo sapiens (human) | Potency | 7.9641 | 0.0025 | 41.7960 | 15,848.9004 | AID1347398 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 56.2341 | 0.1000 | 20.8793 | 79.4328 | AID588453 |
| pregnane X receptor | Rattus norvegicus (Norway rat) | Potency | 79.4328 | 0.0251 | 27.9203 | 501.1870 | AID651751 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 48.9662 | 3.1890 | 29.8841 | 59.4836 | AID1224846 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 68.5896 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 69.1666 | 0.1737 | 34.3047 | 61.8120 | AID1346859 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 28.1838 | 0.0316 | 37.5844 | 354.8130 | AID743255 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 69.1666 | 0.1737 | 34.3047 | 61.8120 | AID1346859 |
| TDP1 protein | Homo sapiens (human) | Potency | 2.9093 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 10.1745 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 43.5795 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID743035; AID743042; AID743054 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 14.5203 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224893 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 79.4328 | 0.5318 | 15.4358 | 37.6858 | AID504845 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 42.8865 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159553; AID1159555 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 68.1351 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1259401; AID1259403 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 50.7163 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982; AID720659 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 68.5896 | 0.0002 | 29.3054 | 16,493.5996 | AID743079 |
| IDH1 | Homo sapiens (human) | Potency | 29.0929 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 1.7783 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 68.5896 | 0.0016 | 28.0151 | 77.1139 | AID1224895 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 15.4845 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 8.8092 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 113.0040 | 0.0391 | 47.5451 | 146.8240 | AID1224845 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 15.8489 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 0.0708 | 0.0100 | 39.5371 | 1,122.0200 | AID588545 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 39.3488 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743066; AID743067 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 54.9410 | 0.0420 | 27.3789 | 61.6448 | AID743210 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 112.2020 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 15.0030 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
| snurportin-1 | Homo sapiens (human) | Potency | 112.2020 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 17.2289 | 0.0006 | 27.2152 | 1,122.0200 | AID743202 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 19.9526 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| geminin | Homo sapiens (human) | Potency | 1.6360 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 35.4813 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| polyadenylate-binding protein 1 | Homo sapiens (human) | IC50 (µMol) | 66.0000 | 4.9100 | 23.7029 | 76.1900 | AID602259; AID602260 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2, isoform CRA_a | Homo sapiens (human) | EC50 (µMol) | 91.1700 | 3.3810 | 3.3810 | 3.3810 | AID686991 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.86) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||